[go: up one dir, main page]

CA2654557A1 - Preparations combinees contenant du bifeprunox et de la l-dopa - Google Patents

Preparations combinees contenant du bifeprunox et de la l-dopa Download PDF

Info

Publication number
CA2654557A1
CA2654557A1 CA002654557A CA2654557A CA2654557A1 CA 2654557 A1 CA2654557 A1 CA 2654557A1 CA 002654557 A CA002654557 A CA 002654557A CA 2654557 A CA2654557 A CA 2654557A CA 2654557 A1 CA2654557 A1 CA 2654557A1
Authority
CA
Canada
Prior art keywords
dopa
bifeprunox
administration
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002654557A
Other languages
English (en)
Inventor
Andrew C. Mccreary
Gustaaf J.M. Van Scharrenburg
Martinus Th. M. Tulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2654557A1 publication Critical patent/CA2654557A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002654557A 2006-06-16 2007-06-15 Preparations combinees contenant du bifeprunox et de la l-dopa Abandoned CA2654557A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
US60/814,052 2006-06-16
EP06115587.5 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (fr) 2006-06-16 2007-06-15 Préparations combinées contenant du bifeprunox et de la l-dopa

Publications (1)

Publication Number Publication Date
CA2654557A1 true CA2654557A1 (fr) 2007-12-21

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002654557A Abandoned CA2654557A1 (fr) 2006-06-16 2007-06-15 Preparations combinees contenant du bifeprunox et de la l-dopa

Country Status (9)

Country Link
EP (1) EP2037964A2 (fr)
JP (1) JP2009539942A (fr)
KR (1) KR20090033871A (fr)
AU (1) AU2007259256A1 (fr)
CA (1) CA2654557A1 (fr)
EA (1) EA014576B1 (fr)
IL (1) IL195493A0 (fr)
NO (1) NO20090165L (fr)
WO (1) WO2007144422A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826478A1 (fr) * 2008-06-30 2015-01-21 Novartis AG Combinaison comprenant mglur modulateurs pour le traitment de la maladie de parkinson
ITMI20100260A1 (it) * 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
EP2627328B1 (fr) * 2010-10-15 2016-09-14 Contera Pharma APS Combinaisons d'agonistes de récepteurs de sérotonine pour le traitement de troubles du mouvement
ES2654787T3 (es) 2012-04-18 2018-02-15 Contera Pharma Aps Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
CA2965379A1 (fr) 2014-10-21 2016-04-28 Abbvie Inc. Promedicaments de carbidopa et l-dopa et methodes d'utilisation
JP7227896B2 (ja) 2016-07-11 2023-02-22 コンテラ ファーマ エー／エス 朝の無動状態を治療するための拍動性薬物送達系
AU2019379806B2 (en) 2018-11-15 2025-08-14 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona

Also Published As

Publication number Publication date
WO2007144422A2 (fr) 2007-12-21
KR20090033871A (ko) 2009-04-06
AU2007259256A1 (en) 2007-12-21
EA014576B1 (ru) 2010-12-30
NO20090165L (no) 2009-01-12
IL195493A0 (en) 2009-09-01
JP2009539942A (ja) 2009-11-19
EP2037964A2 (fr) 2009-03-25
WO2007144422A3 (fr) 2008-03-13
EA200970022A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
Post et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response
Baldessarini et al. Pharmacotherapy of psychosis and mania
JPH0380127B2 (fr)
JP2008519847A (ja) 運動障害の治療方法
CA2654557A1 (fr) Preparations combinees contenant du bifeprunox et de la l-dopa
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
AU2019201575A1 (en) Compositions and methods for treatment of chronic fatigue
JP2025072496A (ja) ジスキネジア治療薬
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
WO2010126527A1 (fr) Méthodes de traitement des affections du snc
US8106056B2 (en) Combination preparations comprising bifeprunox and a dopamine agonist
WO2007144421A1 (fr) Préparations combinées contenant le slv308 et de la l-dopa
WO2020110128A1 (fr) Combinaison de pridopidine et d'un agent thérapeutique additionnel pour le traitement de la dyskinésie induite par un médicament
JP2519148B2 (ja) うつ病治療剤
MX2008016226A (es) Preparaciones de combinacion que comprenden bifeprunox y l-dopa.
HK1130677A (en) Combination preparations comprising bifeprunox and l-dopa
Dalvi Parkinsonism
Vo et al. Guidelines for the Use of Parkinsonian Drugs (in USA)
MX2008016225A (es) Preparaciones de combinacion que comprenden slv308 y l-dopa.
HK1135017A (en) Combination preparations comprising slv308 and a l-dopa

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130617